On 9 August 2012, orphan designation (EU/3/12/1038) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated).
In February 2022, the sponsor’s address was updated and the name was changed from AOP Orphan Pharmaceuticals AG to Aop Orphan Pharmaceuticals GmbH.
Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
EU/3/12/1038: Public summary of opinion on orphan designation: Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemi... (PDF/131.67 KB)
First published: 27/09/2012
Last updated: 27/09/2012
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: